Table 1 Patient and pathology... | American Society of Hematology

Table 1

Patient and pathology characteristics, PCR markers tested on frozen-thawed ovarian tissue, and xenografting experiment results

Patient no.	Age at OTC, y	Pathology	Gonadotoxic chemotherapy before OTC*	Molecular markers	Ovarian tissue PCR	Macroscopic evaluation of grafts	Microscopic evaluation of grafts	Microscopic evaluation of mouse livers
1	31	CML	0	BCR-ABL	Positive	Normal	Normal	Normal
2	17	CML	0	BCR-ABL	Negative	Normal	Normal	Normal
3	30	CML	0	BCR-ABL	Positive	Normal	Normal	Normal
4	19	CML	0	BCR-ABL	Negative	Normal	Normal	Normal
5	32	CML	0	BCR-ABL	Negative	Normal	Normal	Normal
6	19	CML	0	BCR-ABL	Negative	Normal	Normal	Normal
7	15	ALL	1, 8	BCR-ABL	Positive	Normal	Normal	Normal
8	21	ALL	0	E2A-PBX1	Positive	2 leukemic ovarian masses	Leukemic invasion	Normal
9	27	ALL	(2, 3, 4, 5, 6) ×2	Ig and TCR-γ	Negative	Normal	Normal	Normal
10	20	ALL	1, 2, 3, 4, 7, 8	Ig and TCR-γ	Positive	Normal	Normal	Normal
11	12	ALL	0	Ig	Positive	Normal	Normal	Normal
12	15	ALL	1, 2	None	NA	Diffuse leukemic masses	Leukemic invasion	Positive
13	15	ALL	0	Ig	Positive	1 leukemic ovarian mass	Leukemic invasion	Normal
14	14	ALL	0	Ig	Positive	Diffuse leukemic masses	Leukemic invasion	Positive
15	16	ALL	1, 2	Ig	Negative	Normal	Normal	Normal
16	5	ALL	1, 2	Ig and TCR-γ	Negative	Normal	Normal	Normal
17	3	ALL	1, 2	None	NA	Normal	Normal	Normal
18	11	ALL	1, 2	TCR-γ	Positive	Normal	Leukemic invasion	Normal

Patient no.	Age at OTC, y	Pathology	Gonadotoxic chemotherapy before OTC*	Molecular markers	Ovarian tissue PCR	Macroscopic evaluation of grafts	Microscopic evaluation of grafts	Microscopic evaluation of mouse livers
1	31	CML	0	BCR-ABL	Positive	Normal	Normal	Normal
2	17	CML	0	BCR-ABL	Negative	Normal	Normal	Normal
3	30	CML	0	BCR-ABL	Positive	Normal	Normal	Normal
4	19	CML	0	BCR-ABL	Negative	Normal	Normal	Normal
5	32	CML	0	BCR-ABL	Negative	Normal	Normal	Normal
6	19	CML	0	BCR-ABL	Negative	Normal	Normal	Normal
7	15	ALL	1, 8	BCR-ABL	Positive	Normal	Normal	Normal
8	21	ALL	0	E2A-PBX1	Positive	2 leukemic ovarian masses	Leukemic invasion	Normal
9	27	ALL	(2, 3, 4, 5, 6) ×2	Ig and TCR-γ	Negative	Normal	Normal	Normal
10	20	ALL	1, 2, 3, 4, 7, 8	Ig and TCR-γ	Positive	Normal	Normal	Normal
11	12	ALL	0	Ig	Positive	Normal	Normal	Normal
12	15	ALL	1, 2	None	NA	Diffuse leukemic masses	Leukemic invasion	Positive
13	15	ALL	0	Ig	Positive	1 leukemic ovarian mass	Leukemic invasion	Normal
14	14	ALL	0	Ig	Positive	Diffuse leukemic masses	Leukemic invasion	Positive
15	16	ALL	1, 2	Ig	Negative	Normal	Normal	Normal
16	5	ALL	1, 2	Ig and TCR-γ	Negative	Normal	Normal	Normal
17	3	ALL	1, 2	None	NA	Normal	Normal	Normal
18	11	ALL	1, 2	TCR-γ	Positive	Normal	Leukemic invasion	Normal

Data indicate the number of CML and ALL patients, their age at the time of OTC, and the type of gonadotoxic chemotherapy received before OTC. Molecular markers present in blood or bone marrow at the time of diagnosis were tested by PCR on frozen-thawed ovarian tissue. Results of the grafting experiments, showing the macroscopic aspect of the grafts at mouse death, as well as the histology of ovarian xenografts and mouse livers, are also presented. CML patients received hydroxycarbamide with or without imatinib.

OTC indicates ovarian tissue cryopreservation; Ig, immunoglobulin rearrangement genes; TCR, T-cell receptor rearrangement genes; and NA, not appropriate.

1 indicates methotrexate, intrathecally; 2, cortisone, intravenously; 3, cyclophosphamide; 4, vincristine; 5, doxorubicin, 6, cytosine arabinoside; 7, daunorubicin; and 8, asparaginase.

View Large

This Feature Is Available To Subscribers Only